Increasing PrEP Persistence for HIV Prevention

N/A

Waitlist Available

Led By Lawrence C Long, PhD MCom

Research Sponsored by Boston University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Initiating PrEP on the date of enrolment

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 months, 7 months, 13 months

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a new method to help men who have sex with men (MSM) in South Africa continue taking their daily HIV prevention pill. The study uses reminders, commitments, and planning prompts to

Who is the study for?

This trial is for men who have sex with men (MSM) in South Africa, who are starting on PrEP to prevent HIV. Participants must be willing to receive text messages and complete questionnaires. There's no detailed exclusion criteria provided.

What is being tested?

The study tests if reminders, commitment pledges, and planning prompts can help MSM continue taking PrEP consistently. Participants will either get the standard care or this new intervention through mobile phone texts after an initial visit.

What are the potential side effects?

Since the intervention involves behavioral techniques like reminders rather than medication, there are no direct medical side effects expected from participating in this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am starting PrEP on the day I join the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 months, 7 months, 13 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 months, 7 months, 13 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months, 7 months, 13 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability by intervention participants

Fidelity to intervention (feasibility)

Target population recruitment (feasibility)

Secondary study objectives

PrEP persistence at 3 months, 6 months, and 12 months

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention groupExperimental Treatment1 Intervention

Participants randomized into this group will receive a behavioral economics informed intervention to improve persistence among amongst high risk men newly initiating PrEP in South Africa.

Group II: Control groupActive Control1 Intervention

Usual care for high risk men newly initiating PrEP in South Africa.

0 / 1Eligibility criteria met